Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability.
Oxybutynin hydrochloride (3 mg) was compared with placebo by randomised, double-blind crossover trial in 53 females with idiopathic detrusor instability. Symptoms were cured or markedly improved in 60% of patients on oxybutynin and 2.3% on placebo. During the first treatment period, oxybutynin reduced the frequency of voiding by 35%, compared with 9% for placebo. Oxybutynin gave a significantly greater improvement than placebo in volume at the first desire to void (70 ml increase versus 7.7 ml), maximum filling-phase detrusor pressure (17 cm H2O reduction versus no benefit) and cystometric capacity (104 ml increase versus 7.0 ml). A marked oxybutynin carry-over effect was seen during the second treatment period. Side effects from the 3 mg dose of oxybutynin caused 7.5% of subjects to discontinue therapy.
Moore
K H
KH
Department of Gynaecology, Princess Royal Hospital, Hull.
Hay
D M
DM
Imrie
A E
AE
Watson
A
A
Goldstein
M
M
D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008333:Mandelic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010276:Parasympatholytics / Q000627:therapeutic use*; D001745:Urinary Bladder Diseases / Q000188:drug therapy* / Q000503:physiopathology; D014555:Urination Disorders / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics; D014987:Xerostomia / Q000139:chemically induced
D008333:Mandelic Acids; D010276:Parasympatholytics; C005419:oxybutynin